34results about How to "Treat cancer" patented technology

Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.

Methods of inhibiting tumor growth, methods of treating cancer, and methods of reducing the frequency of cancer stem cells in a tumor are described. Particularly, the methods are directed to tumors or cancers that comprise a K-ras mutation. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described.

The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.

The present invention relates to a novel class of hydroxyalkylarylamide derivatives. The instant compounds can be used to treat cancer. The fluorinated arylamide derivatives can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and / or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and / or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the hydroxamic acid derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the hydroxamic acid derivatives in vivo.

The present invention is drawn to immunotherapeutic methods to treat tumors / cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.

The present invention relates to methods and compositions for eliminating circulating tumor cells (CTCs) in a patient with or without solid tumors. In particular, the ex vivo method utilizes a photodynamic or magnetic targeting moiety that specifically binds to antigens expressed on the cell surface of CTCs.

The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.

The present invention is drawn to immunotherapeutic methods to treat tumors / cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.

The present invention is drawn to immunotherapeutic methods to treat tumors / cancers that produce progastrin ectopically or are dependent on progastrin for their growth. Disclosed herein are immunogenic compositions comprising agents that target progastrin, agents that target the progastrin receptor, annexin II, or both. Such a composition may be administered in combination with chemotherapy or to an individual who had been previously subjected to chemotherapy or radiation therapy. The cancers that may be treated using such a composition may include but are not limited to colon cancer, breast cancer, lung cancer or pancreatic cancer.

Various embodiments of this invention disclose a polarized dilute blue scorpion venom solution, a method for making a polarized dilute scorpion venom solution, and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution relieves pain, improves immune-system response, treats cancer, prevents cancer, improves quality of sleep, reduces inflammation, and minimizes negative biological response to chemotherapy and radiation treatment.

The present invention relates to novel therapies for treatment and new biomarkers for earlier detection of pancreatic and other cancers. In particular, the present invention identifies Reg1α and Reg3α, and other members of the Reg protein family, as signaling proteins for a receptor on the surface of human cancer cells, Megi, and the downstream pathways activated through this receptor in pancreatic and other tumor cells. These signaling proteins may be targeted by means known in the art to disrupt the downstream signaling pathway that catalyzes tumorigenesis, by the usage of antibodies, antisense, RNA interference, small molecule inhibitors and vaccines.

The invention describes methods that are useful for treating cancer by administering a Chk1 inhibitor which can induce apoptosis in p53-defective cells when combined with a chemotherapy and / or radiotherapy. Methods for screening candidates for a Chk1 inhibitor-based cancer treatment regimen are also described.

The invention provides a novel class of NIR-absorbing biocompatible organic nanoparticles for effective imaging, targeting and treatment of deep-tissue cancers or tumors. The invention enables a new platform for precise cancer- or tumor-targeting theranostics and clinical cancer treatment.

Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.

Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.

Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions / disorders / diseases due to mutations or dysregulation of the Wnt pathway and / or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

A method for treating cancer and / or preventing or reducing metastasis or treating angiogenesis related disorders comprising as the step of administering IL-31 or peptide which is at least about 70%, homologous to the IL-31 sequence as set forth in SEQ ID No. 1.

Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to tumors, sites of injury and blood clots in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to tumors, sites of injury and blood clots.

The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and / or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and / or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and / or metastasis of the cancer, including remission and cure of the patient's cancer.

Epithelial cell growth inhibitors differentially express in normal and cancerous epithelial cells. The ECGI proteins and nucleic acid sequence encoding them are useful in the diagnosis and treatment of epithelial cell cancers, for example prostate, ovarian, colon cancer, and the like.

Disclosed are methods and devices utilizing bioelectrodynamics for the therapeutic treatment of disorders in a subject in need thereof with an electric field or electromagnetic field therapy. The methods and devices provide an inhibitory effect on growth of cancer cells that are exposed to an electromagnetic field generated by a CETS unit. Cancer cells may arrest proliferation and enter apoptosis by activation of the unfolded protein response (UPR), TNF / TRAIL, and p53 oncogene activation. The methods and devices may be used to enhance wound healing with exposure to an electromagnetic field generated by a CETS unit. Noncancerous cells may show a significant increase in cell migration with no activation of apoptosis pathways.

A method for HIFU treatment of localized prostate cancer in a patient includes identifying the cancer locations in a patient's prostate; visually segmenting the patient's prostate into areas for analysis and treatment, where the section including the area of most aggressive cancer is determined to be the primary area. The primary area is subjected to a first full HIFU treatment for a period intended to ablate the cancerous tumor. HIFU treatment is then stopped on the primary area and the primary area is allowed to rest while simultaneously subjecting the next contiguous area of the patient's prostate to a first HIFU treatment to ablate any additional areas of suspected cancer in the next contiguous area. HIFU treatment is then stopped in the contiguous area. The primary area is then subjected to a second full HIFU treatment for a period sufficient to ensure the complete ablation of the cancerous tumor. The method further includes repeating alternating full HIFU treatment processes on subsequent contiguous areas of the patient's prostate to ensure the complete ablation of any cancerous tumors in the patient's prostate. The entire process is completed under one treatment of anesthesia.

Provided are methods, pharmaceutical compositions and kits for treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of an agent which downregulates a mitochondrial aspartate-dependent pyrimidine synthesis, thereby treating the cancer.

HIFU treatment of localized prostate cancer includes identifying the cancer locations in a patient's prostate and visually segmenting the patient's prostate into areas for analysis and treatment. The section including the most aggressive cancer is determined to be the primary area and subjected to a first full HIFU treatment for a period intended to ablate the cancer. HIFU treatment is then stopped on the primary area, allowing it to rest, while simultaneously subjecting the next contiguous area of the prostate to HIFU treatment to ablate any additional areas of suspected cancer. HIFU treatment is then stopped in the contiguous area. The primary area is then subjected to a second full HIFU treatment for a period sufficient to ensure the complete ablation of the cancerous tumor. Repeating alternating full HIFU treatment on subsequent contiguous areas of the prostate ensures the complete ablation of any cancerous tumors in the prostate.

Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and / or GBP1: pro-survival kinase (e.g. serine / threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and / or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.

The present invention relates to a composition for intracellular delivery containing an adenovirus protein VI-derived peptide and an anti-cancer pharmaceutical composition containing the same. According to the present invention, the use of the peptide or peptide-polymer composite of the present invention improves intracellular delivery efficiency of a nucleic acid, a peptide, a poly-peptide, an antibody, a chemical material, or a virus. Therefore, the peptide or peptide-polymer composite of the present invention can be favorably used as an intracellular delivery system for various therapeutics.

A composition for treating tumors caused by pancreatic, stomach, breast, or liver cancer, leukemia, lung or liver metastasis, and / or arterial aneurysm. The composition comprises in various parts: turtle shell, radix ranunculi ternati, rhizoma dioscoreae bulbiferae, concha arcae, fructus ligustri lucidi, cordyceps sinensis, dwarf lilyturf tuber, Whim brownii, radix astragali, angelica sinensis, radix pseudostellariae, spina date seed, fruit-spike of common selfheal, pericarpium citri reticulatae, costustoot, cape jasmine fruit, radix scrophulariae, radix rehmanniae, rhizoma corydalis, safflower, turmeric root-tuber, cortex moutan, concha ostreae, poria cocoa, herba lysimachiae, the root of red-rooted salvia, isatis indigotica fort, honeysuckle, fructus forsythiae, cortex eucommiae, radix gentianae macrophyllae, radix paeoniae alba, subprostrate sophora, seman platycladi, snakegourd fruit, membrane of chicken gizzard, platycodon grandiflorum, and radix liquiritiae.